Published in Nature Communications · View the paper (DOI)
A new gene-editing system successfully cured a genetic blood disorder in living mice, offering a minimally invasive treatment for beta thalassemia and sickle cell disease. The technology significantly decreases unwanted gene mutations and uses FDA-approved nanoparticles to deliver PNA molecules.
Coverage from 2 institutions